Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.51 |
| ▸ | MGAM | O43451 | 6/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | SI | P14410 | 6/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 6/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28669951 | 0.84 | SLC9A1 (0.60) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL28675633 | 0.84 | SLC9A1 (0.60) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL28650701 | 0.84 | SLC9A1 (0.60) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL19911445 | 0.83 | SLC9A1 (0.58) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL11074730 | 0.81 | GAA (0.52) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL19911444 | 0.80 | SLC9A1 (0.56) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL17103012 | 0.76 | KMO (0.61) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL17103044 | 0.76 | SLC9A1 (0.62) | SLC9A1GAAHCAR3RAB9ANPC1 | |
| SCHEMBL14294674 | 0.75 | SLC9A1 (0.53) | SLC9A1MGAMAMY1AGAASI | |
| SCHEMBL17103090 | 0.75 | SLC9A1 (0.56) | SLC9A1HCAR3RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106420754-B | The purposes of benzo five-membered Azacyclyl bridged piperazine derivatives | 沈阳海王生物技术有限公司 | 2019-11-05 | — | — | CN | disclosed |
| US-9802929-B2 | Benzo five-membered nitrogen heterocyclic piperidine or piperazine derivatives and preparation methods and pharmaceutical compositions thereof | SHENYANG HAIWANG BIOTECHNOLOGY CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20160009703-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | LIAONING EMMY BIOLOGICAL PHARMACEUTICAL CO., LTD (CN) | 2016-01-14 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| EP-2924032-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| CN-103833642-A | Use of benzo five-membered azaheterocyclyl piperazine derivatives | LIAONING BEILEI BIOLOG PHARMACEUTICAL CO LTD | 2014-06-04 | — | — | CN | disclosed |
| CN-103833658-A | Benzotriazole-based piperazine compound as well as preparation method and pharmaceutical composition thereof | LIAONING BEILEI BIOLOG PHARMACEUTICAL CO LTD | 2014-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | SLC9A1 837/4885MGAM 4690/4885AMY1A 2953/4885 |
| US-20160009703-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CYP3A5, IL5, ABCC5 | SLC9A1 1724/4885MGAM 4691/4885AMY1A 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.